Financing led by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex VANCOUVER, BC, July 13, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, is pleased to announce that, further to its news release dated June 30, 2022…
